Fermitin family member 1 (FERMT1, Kindlin-1) is an epithelial-specific regulator of integrin functions and is associated with Kindler syndrome, a genetic disorder characterized by skin blistering, atrophy, and photosensitivity. However, the possible role of kindlin-1 in cancer remains unknown.
Metastasis, which is responsible for most cancer mortality, occurs through a multistep process, including invasion of tumor cells into the adjacent tissues, intravasation, survival in the circulation, extravasation from blood vessels, initiation and maintenance of micrometastases at distant sites, and finally, growth of cancer cells to produce secondary tumors (1) (2) (3) (4) (5) . At each step, metastatic cancer cells face multiple obstacles that are overcome with molecular alterations that modify the expression and function of specific metastasis-related genes (1) (2) (3) 6, 7) .
Since 2000, the application of genomic profiling methods to the analysis of human breast tumors has generated expression profiles that are predictive of metastasis (8) (9) (10) . However, although such analyses are very powerful for identifying prognostic markers, it has been difficult to definitively attribute the development of metastasis to the specific contributions of these genes because of the lack of experimental verification. Furthermore, comparative expression profiling of cancer cells with different metastatic potentials in animal models has led to the identification of metastasis promoting genes (8, (11) (12) (13) (14) , although much work remains to be done to validate their clinical relevance. Thus, the characterization of both clinically relevant and functionally important metastasis genes is a crucial step toward the identification of potential therapeutic targets for prevention and treatment.
In previous transcriptomic studies of human metastatic samples (15, 16) , we identified Fermitin family member 1 (FERMT1), also called Kindlin-1, in a six-gene signature that discriminates primary breast tumors with higher propensity to metastasize to the lungs. Although this signature was suggested to be a surrogate of the ARTICLE Role of the Focal Adhesion Protein Kindlin-1 in Breast Cancer Growth and Lung Metastasis basal-like subtype of breast cancers, we further demonstrated that it predicts lung metastases independent of the molecular subtypes of breast tumors (16, 17) .
Kindlin-1 encodes the kindlin-1 protein that belongs to a family of focal adhesion proteins consisting of three members (kindlin-1 to 3). Kindlins have clinical relevance for several human genetic disorders (18) (19) (20) (21) . In particular, Kindlin-1 is mutated in Kindler syndrome, a genetic skin pathology characterized by skin blistering, atrophy, and photosensitivity (18, 19, 22) . Kindlins are regulators of integrin signaling and cell-matrix adhesion (23) . They were shown to directly bind to b-integrin cytoplasmic tails. This binding, in concert with talin recruitment, leads to the activation (inside-out signaling) of integrins, enabling them to bind to their ligands (20) . Following ligand binding, kindlins recruit integrinlinked kinase (ILK) and migfilin to focal adhesion sites (outside-in signaling), thereby linking the extracellular matrix (ECM) to the actin cytoskeleton (24) . In line with this adapter function, kindlin-1-deficient cells exhibit defects in b1 integrin activation and impaired cell adhesion, proliferation, polarity, and motility (22, 25, 26) .
Most kindlin-related studies focus on kindlin relevance in skin disease. To date, the biological implications of kindlin-1 have not been shown in cancer. Here, we conducted a study to investigate the role of kindlin-1 at the clinical, cellular, and molecular levels. First, we investigated whether Kindlin-1 is associated with lung metastasis in human breast cancer and poor prognosis in lung cancer. We then addressed the role of kindlin-1 in the aggressive phenotypes of tumor cells and assessed its involvement in breast cancer progression using an orthotopic mouse model.
Methods

Patients and Cell Lines
Patients. Lung, liver, brain, and bone metastases from breast cancer patients were obtained from the Curie Institute/René Huguenin Hospital (Saint-Cloud, France), the University of L'Aquila (L'Aquila, Italy), and IDIBELL (Barcelona, Spain). In addition, the microarray expression profiles of breast cancer metastases from an independent cohort of patients were analyzed (27) .
A total of 516 primary tumors were obtained from the Curie Institute/René Huguenin Hospital. Of those, 502 [66 grade 1, 261 grade 2, and 175 grade 3 tumors, as scored according to Bloom and Richardson histoprognostic grading (28) ; see Supplementary Table 1 , available online] were selected to encompass the various stages of breast cancer progression because grading information was available on those patients. The mean age of the patients was 60.7 years (range = 25-91 years), and the median follow-up was 120.5 months (range = 13-347 months). Seventy-six patients developed lung metastases.
We also analyzed four independent datasets of breast tumors (29) (30) (31) (32) (33) and two cohorts of lung cancers (34, 35) for which microarray data were publicly available. The breast cancer cohorts "TRANSBIG"(consortium of the Breast International Group, n = 198; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE7390), "EMC" (Erasmus Medical Center, n = 344; http://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc=GSE2034 and GSE5327), and "NKI" (Netherlands Cancer Institute, n = 295; http://microarray-pubs. stanford.edu/wound_NKI/) consisted of early-stage breast tumors (100%, 100%, and 50% lymph node negative, respectively), whereas the "MSKCC" (Memorial Sloan-Kettering Cancer Center; http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2603) cohort (n = 82) consisted of locally advanced tumors (66% lymph node positive).
Paraffin-embedded sections of matching breast tumors and metastases (n = 22) were obtained from the Curie Institute/René Huguenin Hospital and the University of Liège (Belgium). Adjacent normal host tissues were also observed in the same sections.
Written informed consent was obtained from each patient according to the recommendations of the local ethics committee. This study was approved by the review boards and ethics committees of the respective institutions.
Cell Lines. Mouse mammary tumor cell lines 67NR, 168 FARN, 4T07, and 4T1 were kindly provided by Dr Fred Miller (Karmanos Cancer Institute/Wayne State University, Detroit, MI). Human mammary epithelial cells (HMEC) were purchased from Lonza (Walkersville, MA). All other human mammary cell lines HBL-100, MCF7, SK-BR-3, MDA-MB-231, MDA-MB-468, and MDA-MB-435S were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Currently, it is unclear whether MDA-MB-435S is a breast cancer line, because it may
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Prior knowledge
Kindlin-1 encodes one of the three kindlin proteins implicated in several human genetic disorders, including Kindler syndrome, a genetic skin pathology characterized by blistering, atrophy, and photosensitivity. Kindlin-1 may also play a role in several cancers, but the nature of that role is unknown.
Study design
The effects of kindlin-1 overexpression and silencing on cell signaling and metastasis-like functions were assessed in human breast cancer cell lines and in breast tumor growth and lung metastasis in mice. The association between kindlin-1 expression and metastasis-free survival was analyzed in tumor tissue from 516 breast cancer patients.
Contribution
Kindlin-1 expression in human breast tumors was statistically significantly associated with lung metastasis and lung metastasis-free survival. Kindlin-1-expressing cells displayed characteristics that are hallmarks of metastasis, whereas Kindlin-1-silencing prevented tumor growth and lung metastasis in mice.
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Kindlin-1 expression may be useful in identifying breast cancer patients with higher risk of developing lung metastasis. In addition, targeting kindlin-1 function may be an effective strategy for blocking metastasis in breast and other cancers.
Limitations
Kindlin-1 expression in other cancers besides breast cancer, which metastasize to the lungs, was not assessed. Although kindlin-1 expression was associated with other genes important in metastasis initiation, the molecular dissection of this association was not addressed.
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actually be a melanoma line (36) . The phenotype of HMEC cells was verified by Lonza by immunostaining for specific markers, and a certificate of analysis confirmed the authentication of cells. The phenotypes of the other cells were verified by ATCC by immunostaining for specific markers. The protocols for verifying the cell lines are available on the ATCC Web site (http://www.atcc.org /Portals/1/Pdf/CellBiologyStandards.pdf). The cell lines 67NR, 168 FARN, and 4T07 were used before passage 20, and the 4T1 cell line was used before passage 13.
All cell lines were maintained at 37°C with 5% CO 2 and grown in Dulbecco's Minimal Essential Medium (DMEM), supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) or 5% FBS [168FARN and 4T1, as previously described (37) ] or in Minimal Essential Medium (MCF7) and 1% antibiotics (50 µg/mL penicillin, 50 µg/mL streptomycin, 100 µg/mL neomycin). Transforming growth factor b1 (TGFb1) and transforming growth factor b receptor 1 (TGFbR1) inhibitor (SB431542) targeting the kinase activity of TGFbR1, were purchased from R&D Systems, Inc (Minneapolis, MN), and Sigma-Aldrich (St Louis, MO), respectively.
Constructs and Transfections
Expression Constructs. The human Kindlin-1 cDNA, kindly provided by Dr Beckerle (Huntsman Cancer Institute, Salt Lake City, UT), was subcloned into the phCMV2-HA and pIREShyg3 vectors. Transfections were performed using Lipofectamine Reagent (Invitrogen) following the manufacturer's instructions. Stable transfectants were grown in the presence of 1 mg/mL geneticin G418 or 50 µg/mL hygromycin (Sigma-Aldrich). At least two clones of each cell line were used for in vitro experiments to exclude clonal variation.
Luciferase Reporter Assay. For TGFb-inducible luciferase reporter assays, MDA-MB-231 cells were transfected with the p3TP-lux construct that is a TGFb1-responsive firefly luciferase reporter gene that contains three consecutive tetradecanoylphorbol acetate (TPA) response elements (TREs) and a portion of the plasminogen activator inhibitor 1 (PAI-1) promoter region (Wrana and Massague, Memorial Sloan-Kettering Cancer Center, New York, NY) (38) . For the E-cadherin (CDH1) promoter luciferase reporter assay, we used pGL3-E-cad(2178/+92) (WT) containing the wild-type CDH1 promoter or pGL3-E-cad(2178/+92) (MUT) containing the promoter with mutated E-boxes, kindly given by Dr Batlle (ICREA/IRB, Barcelona, Spain) and previously described (39) . In all luciferase experiments, cells were cotransfected with pIREShyg3-Kindlin-1 or pIREShyg3 as control and with pRL-TK (Stratagene, La Jolla, CA), which constitutively expressed Renilla luciferase as an internal standard for the variation of transfection efficiency.
Small Interfering RNA (siRNA)-Mediated RNA Interference. Two different siRNA-coding oligonucleotides against human Kindlin-1 (Dharmacon, Lafayette, CO) were tested. The Kindlin-1-siRNA1-targeting sequence is 5′-CAGCUGCUCUUACGAUUUA-3′ (only sense sequence is shown). The Kindlin-1-siRNA2-targeting sequence is 5′-AAACCCAGAUCCUCAGUUA-3′. A non-targeting siRNA oligonucleotide, which did not match any known human coding cDNA, was used as a control (D-001210-03, Dharmacon). Cells were transfected with Hiperfect Reagent (Qiagen, Valencia, CA).
Stable Knockdown. To establish stable silencing of Kindlin-1, 4T1 cells were transduced with either Kindlin-1 short hairpin RNA (shRNA) (two different shRNA were used: SH-041378-01-25 and SH-041378-02-25) or control non-targeting shRNA lentiviral particles (S-005000-01; SMART vector Lentiviral Particules, Dharmacon) using MOI 200 (Multiplicity Of Infection represents the number of transducing lentiviral particles per cell) for 7 hours in six-well plates in the presence of hexadimethrine bromide (5 µg/mL, Sigma-Aldrich). Transduced cells were subjected to selection with 2 µg/mL puromycin (Sigma-Aldrich).
Expression Analyses
Quantitative Real-Time Polymerase Chain Reaction(qRT-PCR). Total RNA extraction, cDNA synthesis, PCR conditions, and normalization methods were described in detail elsewhere (40) . Briefly, total RNA was isolated using a standard acid-phenol guanidium method. RNA concentration and purity were measured on the Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE). First-strand cDNA was synthesized using a SuperScriptII Reverse Transcriptase kit (Invitrogen) according to the manufacturer's guidelines. All PCR reactions were performed with an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Carlsbad, CA) and the SYBR Green PCR Core Reagents kit (Applied Biosystems). TATA box-binding protein (TBP) transcripts were used as an endogenous RNA control, and each sample was normalized on the basis of its TBP content (40) . Kindlin-1-specific primers were forward: 5′AAG GAA CTT GAA CAA GGA GAA CCA CT 3′ and reverse: 5′ GGC ACA ACT TCG CAG CCT CTA 3′. For each primer pairs a standard curve was performed using a serial dilution of a pool of cDNAs consisting of several normal tissues (placenta, fetal brain, testis, and breast). The linearity of standard curves was verified, with all coefficients of variation between 0.96 and 0.99. Antibody Production. Polyclonal antibodies against kindlin-1 were generated by inoculating rabbits with two distinct human kindlin-1 peptides corresponding to amino acids 652-666 (FLSTRSKDQNETLDE) and amino acids 663-677 (TLDEDLFHKLTGGQD) (Eurogentec, Seraing, Belgium). Antibodies were affinity purified on a sepharose matrix.
Immunohistochemistry. Human and murine tumor paraffin sections were prepared as described (15) . Briefly, tumor blocks were deparaffinized, treated with 3% H 2 O 2 , and incubated with rabbit polyclonal anti-kindlin-1 (1:500; Abcam, Cambridge, MA) or rabbit polyclonal anti-E-cadherin (4A2C7 clone, 1:500; Invitrogen). The staining signals were revealed with the Dako Real Detection System, Peroxidase/AEC kit (Dako, Ely, UK). The slides were counterstained with Mayer's hematoxylin.
Western Blotting. Proteins were extracted from cells in culture using TNMG buffer (20 mM Tris-HCl (pH 8), 150 mM NaCl, 5 mM MgCl 2 , 10% glycerol, 0.5% NP-40, pH 8) supplemented with protease inhibitors. Cell lysates were probed using the following antibodies: mouse monoclonal anti-a-smooth muscle actin (1A4 clone, 1:500), goat polyclonal anti-b-actin (I-19 clone, 1:200), rabbit polyclonal anti-fibronectin (H-300 clone, 1:1000), goat polyclonal anti-GAPDH (V18 clone, 1:2000), rabbit polyclonal anti-Twist-related protein 1 (H-81 clone, 1:200), and rabbit polyclonal anti-vimentin (S-20 clone, 1:1000) all purchased from Santa Cruz Biotechnology (Santa Cruz, CA); mouse monoclonal anti-E-cadherin (clone 36, 1:5000), mouse monoclonal anti-gcatenin (15 clone, 1:5000), and mouse monoclonal anti-N-cadherin (clone 32, 1:2500) from BD Biosciences (San Jose, CA); rabbit monoclonal anti-zinc finger protein snail homolog 1 (SNAI1) (C15D3 clone, 1:100), rabbit monoclonal anti-zinc finger protein SNAI2 (C19G7 clone, 1:100), rabbit polyclonal anti-bcatenin (1: 200), rabbit monoclonal anti-phospho-SMAD family homolog (Smad) 2 (S423-425) (clone 25A9, 1:1000), rabbit monoclonal anti-phospho-Smad3 (S465-467) (clone 138D4, 1:1000), and rabbit polyclonal Smad2/3 (1:1000) obtained from Cell Signaling Technology (Danvers, MA). Proteins were detected according to the ECL Western Blotting Analysis System procedure (GE Healthcare, Buckinghamshire, UK). The quantifications were performed using a video camera (Bio-print system; VilberLourmat, Marne la Vallée, France). Optical densitometry was performed using Bio1D software (Vilber-Lourmat). Immunofluorescence. MCF7 and MDA-MB-435S cells were seeded in 24-well plates pre-coated with 5 µg/mL laminin-111, fixed and permeabilized for 10 min with Phosphate Buffered Saline (PBS) containing 4% paraformaldehyde/0.3% triton, and incubated with PBS containing 1.5% bovine serum albumin (BSA). F-actin was localized using fluorescent-labeled phalloidin conjugated to tetramethylrhodamine isothiocyanate (Sigma-Aldrich) at a dilution of 1:100 of a methanolic stock (200 U/mL) solution. Epithelial and mesenchymal markers were labeled with the same antibodies as used for western blots, except for mouse monoclonal anti-ZO-1 antibody (1/ZO-1 clone, 1:5000; BD Biosciences). Cells were then stained with PBS containing 1 µg/ml DAPI (diamidino-2-phenylindole) to visualize the nuclei. Sections were washed in 0.07 M PBS, mounted, and examined with a fluorescence microscope (Eclipse Ti-S Nikon, Melville, NY).
Cellular Assays
Transwell Migration Assay. Migration assays were performed in triplicate using cell culture inserts with 8.0-µm pore size membranes (Becton Dickinson, Franklin Lakes, NJ) according to the manufacturer's protocol. MCF7 cells (5 × 10 4 ) were plated in the top chamber in DMEM. In the bottom chamber, culture medium containing 10% FBS was used as a chemoattractant. For invasion assays, the top chamber was pre-coated with 4 µg/cm 2 of Matrigel (BD Biosciences). Twenty four hours later, cells were fixed, stained using crystal violet, and counted to estimate total membrane area.
Collagen I Invasion Assay. The following precooled components were gently combined and defined as type I collagen solution: four volumes of type I collagen (stock is 3.49 mg/mL), five volumes of calcium-and magnesium-free Hank's balanced salt solution, one volume of MEM (10×), one volume of 0.25M NaHCO 3 , 2.65 volumes of culture medium, and 0.3 volumes of 1 M NaOH. For each test condition, 1.25 mL of type I collagen solution was added to one well of a six-well plate, homogeneously spread, and solidified on a flat surface in a humidified atmosphere of 10% CO 2 in air at 37°C for at least 1 hour. Control or Kindlin-1 transfected MCF7 single cells (2 × 10 5 ) suspended in 1 mL culture medium were seeded on top of the type I collagen gel and incubated on a flat surface in a humidified atmosphere of 10% CO 2 in air at 37°C. Cell morphology was studied and invasion was scored after 24 hours (41) . The number of invasive and noninvasive cells was counted in ten randomly selected microscopic fields of objective 20× using an inverted phase contrast microscope (DMI 3000B; Leica, Wetzlar, Germany). The invasion index was calculated as the ratio of the number of cells that invaded the gel divided by the number of noninvasive cells counted in each field.
Wound Healing Assay. MDA-MB-435S cells were cultured to confluence in 24-well plates pre-coated with 5 µg/mL laminin-111. Monolayers were scratched with a pipette tip and washed with PBS twice to remove debris. Cells were maintained in DMEM with 10% FBS and antibiotics and imaged by phase contrast microscopy (Eclipse TS100, Nikon). Images were captured at the time and 24 hours after scratching.
Transcriptional Reporter Assay. MCF7 and MDA-MB-231 cells (6 × 10 4 ) were seeded in 24-well plates for 24 hours. Cells were cotransfected with 0.3 µg of luciferase reporter constructs (p3TP-lux, pGL3-E-cad(2178/+92) WT or pGL3-E-cad(2178/+92) MUT) and 1 µg of pIREShyg3-Kindlin-1 or pIREShyg3 as a control, and 0.03 µg of pRL-TK Renilla. Two days after transfection, cell extracts were prepared and the luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega), following the manufacturer's instructions. Luciferase readings were recorded using a luminometer (Berthold Technologies, Bad Wildbad, Germany). Luciferase activity was normalized to Renilla luciferase activity.
Mouse Studies
All mouse experiments were conducted according to French veterinary guidelines, the Curie Institute guidelines on animal care, and those formulated by the council of Europe for experimental animal use (L358-86/609EEC). Transduced 4T1 cells (5 × 10 5 ) were injected subcutaneously into the fourth mammary gland of 12-week-old female BALB/c mice (n = 10 controls and n = 6 Kindlin-1-knockdown mice). Twenty-four days later, all mice were killed by cervical dislocation, and primary tumors and lungs were removed, measured with calipers, and photographed. Tumor volumes were calculated as: volume (cm 3 ) = a × b 2 /2 (a and b are the two registered perpendicular diameters, with a > b). Serial lung sections (every 300 µm) were stained with Mayer's hematoxylin. The number of metastatic foci was determined in a blinded manner by two independent anatomopathologists.
Statistical Analysis
All statistical calculations were performed using PASW Statistics (version 18.0; SPSS Inc, Chicago, IL). Comparisons were performed using a two-sided unpaired Student t test. All experimental data presented are representative of at least two independent experiments performed in triplicate. To determine whether Kindlin-1 expression levels were able to define low-and high-lung metastasis risk populations, the optimal cutoff point to categorize patients into the two distinct risk groups was evaluated by use of the receiver operating characteristic method in the training set (n = 516 and 62 for breast and lung cancer, respectively) and then applied to the validation sets (MSKCC, EMC, NKI, or combined cohort for breast cancer and Memorial Sloan-Kettering Cancer Center, Dana-Farber Cancer Institute, or combined cohort for lung cancer). Survival distributions were estimated by the KaplanMeier method, and the significance of differences between survival rates was ascertained using the log-rank test. Multivariable analysis using Cox proportional hazards model was used to assess the independent contribution of each variable to lung metastasis-free survival. All variables included in the Cox model were categorical: estrogen receptor status was considered negative or positive according to the anatomopathological examination; lymph node status was referred to as positive when at least one lymph node was affected; the basal-like subtype was evaluated according to the intrinsic gene signature (42) , and the "Lung Metastasis Signature" as reported in Minn et al. (12) . The proportional hazards assumption was tested using tests and graphs based on the Schoenfeld residuals.
Oncomine database queries (https://www.oncomine.org) were performed using the same criteria for all tested cancer types. Briefly, we searched all of the gene expression datasets for the Kindlin-1 gene in the "cancer versus normal analysis" category. To avoid discrepancies among the results, we used the same Affymetrix probe (218796_at) Affymetrix, Santa Clara, CA. All studies are presented in the results section, except two out of four datasets on prostate cancer because they all gave similar results.
All statistical tests were two-sided. P values less than .05 were considered to be statistically significant, and where appropriate, the difference in means and the 95% confidence interval (95% CI) are indicated.
Results
Evaluation of Kindlin-1 as a Breast Cancer Lung MetastasisAssociated Gene
We previously identified (15) Kindlin-1 as a highly differentially expressed gene in lung metastases from primary breast tumors compared with metastases in other organs (6.9-fold increase, P < .001, Student t test). These microarray results have been confirmed both at the mRNA and protein levels in additional samples of metastases (Supplementary Figure 1, A and B Figure 1, B , available online), indicating that kindlin-1 is specifically expressed by cancer cells. Non-lung metastases showed low to no kindlin-1 expression (Supplementary Figure 1, B, available online) .
Because kindlin-1 was also detected in primary breast tumors metastasizing to the lungs (15,16), we further investigated whether its expression was associated with breast cancer progression in a series of 198 primary tumors (lymph node-negative systemically untreated patients) (33) . Transcript levels increased with the tumor grade (mean normalized mRNA levels: grade 1-2 vs grade 3, 3.37 vs 3.94; difference = 0.57, 95% CI = 0.13 to 1.01, P = .01, Figure 1 , A) and were higher in lung metastases than in primary tumors (mean normalized mRNA levels: grade 1-2 vs lung metastases, 3.37 vs 5.03, difference = 1.66, 95% CI = 1.00 to 2.31, P < .001; grade 3 vs lung metastases, 3.94 vs 5.03, difference = 1.09, 95% CI = 0.12 to 2.05, P = .02, Figure 1, A) .
Moreover, we analyzed whether kindlin-1 is differentially expressed in breast tumors according to the metastatic site. Kindlin-1 expression was tested by qRT-PCR on an additional sample of 516 primary breast tumors with a well-documented clinical follow-up (Supplementary Table 1 , available online). Higher expression was observed in tumors metastasizing to the lung than in tumors metastasizing to bone (mean normalized mRNA levels: lung-metastasizing tumors vs bone-metastasizing tumors, 1.58 vs 0.69, difference = 0.89, 95% CI = 0.33 to 1.46, P = .002, Figure 1, B) . Immunohistochemical analysis of primary tumors and subsequent metastases (n = 22) confirmed that patients metastasizing to the lungs had strong immunoreactivity in their primary tumors and their lung metastases, but not in their non-lung metastases (Figure 1, C) .
Kindlin-1 as a Prognostic Factor for Breast Cancer Lung Metastasis
To test the prognostic value of Kindlin-1 expression, we performed a univariate analysis on the same sample of tumors from 516 patients (training set). We defined the stratification cutoff to classify patients into high-and low-Kindlin-1 groups in the training set and generated Kaplan-Meier plots to illustrate the survival differences among these groups for both the training and validation (n = 721) datasets (Figure 1 , D and E and Supplementary Figure 2 , A and B). Survival analyses revealed that the risk of lung metastasis was statistically significantly higher for patients with increased Kindlin-1 mRNA levels (lung metastasis-free survival: training set, hazard ratio [HR] of lung metastasis = 1.85, 95% CI = 1.00 to 3.43, P = .03; validation set, HR of lung metastasis = 2.55, 95% CI = 1.39 to 4.69, P = .001, log-rank test). In contrast, we found no association between Kindlin-1 expression and the outcome with regard to overall distant metastasis or specific bone metastasis (Supplementary Figure 2 , C-E, available online).
To determine whether Kindlin-1 is associated with a poor prognosis subtype of breast cancer, we analyzed Kindlin-1 expression in the NKI cohort that was categorized into five molecular subgroups as defined by the "intrinsic signature" (42) . Indeed, the basal subgroup with the worst survival rates had the highest levels of Kindlin-1 transcripts (P < .001, Student t test, Supplementary  Figure 2 , F, available online) indicating that kindlin-1 is a marker of breast tumor aggressiveness and is potentially linked to the basal-like phenotype.
Finally, we performed a multivariable Cox proportional hazards analysis on the validation dataset (n = 721) including the variables Kindlin-1 expression, estrogen receptor status, lymph node status, basal-like subtype, and the Lung Metastasis Signature derived from a MDA-MB-231 xenograft mouse model (12) . Kindlin-1 expression was the only parameter statistically significantly associated with the risk of breast tumors metastasizing to the lungs (Supplementary Table 2 , available online). Table 1 , available online). Means and upper 95% CIs are shown for one experiment. P = .002, Student t test. C) Representative immunohistochemical staining of kindlin-1 in matched pairs of primary tumors and metastases from two individuals with breast cancer from a larger sample (n = 22). Non-lung metastases were harvested from the bone (top) and uterus (bottom) of patient 1, and from the liver (top) and spleen (bottom) of patient 2. Original magnification ×400, scale bar = 50 µm. D) Kaplan-Meier curves showing the lung metastasis-free survival of patients with tumors expressing high vs low levels of Kindlin-1 in the training set of 516 breast cancer patients analyzed by qRT-PCR, HR of lung metastasis = 1.85, 95% CI = 1.00 to 3.43, P = .03. E) Kaplan-Meier curves showing the lung metastasis-free survival of patients with tumors expressing high vs low levels of Kindlin-1 in the combined cohort of 721 breast cancer patients corresponding to three independent microarray datasets (29) (30) (31) (32) , HR of lung metastasis = 2.55, 95% CI = 1.39 to 4.69; P = .001, log-rank test. All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio; qRT-PCR = quantitative realtime polymerase chain reaction.
Kindlin-1 Expression in Other Types of Epithelial Tumors and Association With the Prognosis of Lung Adenocarcinomas
We analyzed microarray datasets in the Oncomine database to determine whether Kindlin-1 could be involved in other cancers metastasizing to the lungs. We found that Kindlin-1 transcripts were consistently higher in tumors than in normal tissues in various cancer types metastasizing to the lungs, including colon cancer (mean normalized mRNA levels in normal vs cancerous tissue: cohort 1, 1.81 vs 2.33, difference = 0.51, 95% CI = 0.44 to 0.59, P < .001; cohort 2, 1.99 vs 2.61, difference = 20.62, 95% CI = 20.75 to 20.48, P < .001) (43, 44) and bladder cancer (mean normalized mRNA levels in normal vs cancerous tissue: cohort 1, 20.27 vs 0.77, difference = 1.04, 95% CI = 0.78 to 1.29, P < .001; cohort 2, 1.10 vs 1.53, difference = 0.42, 95% CI = 0.20 to 0.64, P < .001) (45, 46) (Figure 2, A) . In contrast, Kindlin-1 did not show any overexpression in cancers that do not spread to the lungs such as prostate (mean normalized mRNA levels in normal vs cancerous tissue: (Figure 2, B) .
Notably, we also found overexpression of Kindlin-1 in lung cancers (mean normalized mRNA levels in normal vs cancerous tissue: cohort 1, 0.05 vs 0.51, difference = 0.50, 95% CI = 0.36 to 0.56, P < .001; cohort 2, 20.91 vs 20.30, difference = 0.61, 95% CI = 0.36 to 0.87, P < .001; cohort 3, 0.08 vs 0.87, difference = 0.79, 95% CI = 0.56 to 1.03, P < .001) (49-51) (Figure 2, C) . Therefore, we tested whether Kindlin-1 expression was associated with metastasisfree survival of lung cancer patients. A training set of 62 patients with lung adenocarcinomas (34) were examined for Kindlin-1 expression. The optimal cutoff to stratify patients into high-and low-Kindlin-1 groups was determined by use of the receiver operating characteristic method in this cohort of patients and was applied to a validation set of tumors from 166 patients (35) . Kaplan-Meier analyses of the validation cohort were used to assess the prognostic value of Kindlin-1 expression in lung adenocarcinomas and showed that patients expressing high levels of Kindlin-1 had shorter metastasis-free survival times (metastasis-free survival: training set, HR for metastasis = 3.41, 95% CI = 1.69 to 6.89, P < .001; validation set, HR = 1.96, 95% CI = 1.25 to 3.07, P = .001, log-rank test, Figure 2 , D and Supplementary Figure 3, A-B) .
Effect of Kindlin-1 on the Metastatic Capacities of Breast Cancer Cell Lines
Kindlin-1 expression was higher in invasive and metastatic human tumor cell lines (MDA-MB-231 and MDA-MB-468) than in poorly invasive cell lines (MCF7 and SKBR3) (Figure 3, A) . Moreover, kindlin-1 was only expressed in the highly metastatic 4T1 cells but not in the three nonmetastatic cell lines (67NR, 168FARN, 4T07), all derived from a single mouse mammary tumor (36) . These observations suggest that kindlin-1 increases the metastatic capacities of breast cancer cells. To further investigate this hypothesis, we assessed the effect of stable Kindlin-1 expression in MCF7 cells on proliferation and clonogenicity. According to the proliferation assay, the number of Kindlin-1-cells was 2.7-fold higher than the control cells at 96 hours (Proliferation as measured by optical density at 490 nm for control cells vs Kindlin-1-cells, 0.25 vs 0.68, difference = 0.42, 95% CI = 0.34 to 0.51, P < .001, Figure 3, B) . Moreover, the Kindlin-1-cells were more clonogenic than controls. Notably, control cells formed tighter and more compact colonies, whereas the Kindlin-1 colonies had a dispersed pattern, which may reflect the effects of kindlin-1 on cell spreading, migration, and invasion (Figure 3, C) . Indeed, control cells were minimally motile, whereas Kindlin-1 cells showed statistically significantly more cell migration (number of migrating cells, Kindlin-1-cells vs control, 164.66 vs 19.00, difference = 145.6, 95% CI = 79.1 to 212.2, P = .004, Figure 3, D) . This result was confirmed using a wound healing assay with MDA-MB-435S cancer cells. Kindlin-1 cells showed a more extensive wound closure area with individual random migratory cell behavior compared with control cells (Figure 3, E) . Kindlin-1-MCF7 cells were much more invasive through a native collagentype I matrix (invasion rate, Kindlin-1 cells vs control = 9.65% vs 1.92%: difference = 7.73%, 95% CI = 4.75% to 10.70%, P < .001, Figure 3 , F). In addition, Kindlin-1-cells showed increased local spreading with formation of cell extensions, whereas control cells had a typical epithelial morphology (Figure 3, G) . Moreover, two distinct shRNA showing a similar extinction of Kindlin-1 expression reduced the migratory and invasive capacities of 4T1 cells (Supplementary Figure 4, A-C) .
Implication of Kindlin-1 in the Epithelial-Mesenchymal Transition
We next explored whether Kindlin-1 overexpression in MCF7 and MDA-MB-435S cells induces morphological changes and cytoskeleton reorganization. Indeed, Kindlin-1 cells exhibited a disruption in cell contacts, a spindle-shaped and round morphology, and the formation of actin stress fibers and lamellipodia, which are hallmarks of the epithelial-mesenchymal transition (EMT) and cell motility (Figure 4, A) . Moreover, Kindlin-1 cells had increased levels of mesenchymal markers and decreased levels of epithelial markers, consistent with a Kindlin-1 mediated EMT (Figure 4 , B and C). In addition, Kindlin-1-MCF7 cells had more diffuse staining of E-cadherin, in contrast to the membrane-localized staining in the control lines (Figure 4, D) , suggesting that kindlin-1 overexpression also leads to a redistribution of E-cadherin from the membrane to the cytoplasm.
We used a luciferase reporter assay to examine whether kindlin-1 represses transcription of the E-cadherin gene (CDH1). Cells overexpressing Kindlin-1 had lower CDH1 promoter activity than control cells (50% decrease in luciferase activity relative to control, difference in fold change: 0.52, 95% CI = 0.43 to 0.60, P = .001, Figure 4 , E). Mutation of the E-boxes, which are critical for transcriptional repression of CDH1 (39) , abrogated the effect of kindlin-1 on the CDH1 promoter (Figure 4, E) . Moreover, we found that kindlin-1 stimulates the expression of zinc finger protein SNAI2 and Twist-related protein 1, two major CDH1 repressors (8.5-and 5.4-fold change in relative mRNA levels, respectively), whereas the expression of the zinc finger protein SNAI1 repressor was unaffected (Figure 4, F and data not shown) .
Kindlin-1 and TGFb Reciprocal Signaling Crosstalk
Because kindlin-1 expression was induced by TGFb in normal mammary epithelial cells (HMECs) (25) , and TGFb is a key player in EMT, we analyzed the role of kindlin-1 in TGFb signaling. We used a luciferase reporter assay to determine if TGFb-dependent transcription is activated in MDA-BM-231 cells expressing Kindlin-1 compared with control cells (40% increase in luciferase activity relative to control, difference in fold change: 0.39, 95% CI = 0.06 to 0.73, P = .03, Figure 5 , A). This activation was confirmed in MCF7 cells expressing Kindlin-1 showing a robust induction of phosphorylated Smad-2 and Smad-3, two downstream effectors of the canonical TGFb pathway (Figure 5, B) . oncomine.org). Differences between normal (light blue) and cancerous (dark blue) tissues are shown for two colon cancer datasets (cohort 1, P < .001; cohort 2, P < .001, Student t test) (43, 44) and two bladder cancer datasets (cohort #1: P < .001, and cohort #2: P < .001, Student t test) (45, 46) . B) Kindlin-1 expression in tissue from tumors not metastasizing to the lungs. Box plots of Kindlin-1 expression levels (normalized expression units) in independent microarray studies obtained from the Oncomine database (https://www.oncomine.org). Differences between normal (light blue) and cancerous (dark blue) tissues are shown for two prostate cancer datasets (cohort 1, P = .26; cohort #2, P = .45, Student t test) (47, 48) and two ovarian cancer datasets (cohort 1, P = .61; cohort 2, P = .01, Student t test). C) Three lung cancer datasets (cohort 1, P < .001; cohort 2, P < .001; cohort 3, P < .001, Student t test) (49) (50) (51) . D) Metastasis-free survival rates of a training set of 62 lung cancer patients (34) with tumors expressing high vs low levels of Kindlin-1 and an independent validation set consisting of 166 patients with lung adenocarcinomas (metastasis-free survival: training set, HR of metastasis = 3.41, 95% CI = 1.69 to 6.89, P < .001; validation set, HR of metastasis = 1.96, 95% CI = 1.25 to 3.07, P = .001, log-rank test) (35) . All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio.
To confirm the activation of TGFb signaling, we evaluated the expression levels of several TGFb target genes that are critical in promoting metastasis (53, 54) in Kindlin-1-overexpressing MCF7 cells and Kindlin-1-depleted HMEC cells. Consistent with our previous results ( Figure 5, A and B) , the expression of several TGFb target genes including connective tissue growth factor (CTGF), Morphological changes between control and Kindlin-1 cells growing on laminin substrate (5 µg/mL) as observed by immunofluorescence microscopy in MCF7 and MDA-MB-435S cells. The cytoskeletal reorganization was visualized by F-actin labeling. The arrow shows a lamellipodia-like structure. Scale bar = 20 µm. B) Expression of EMT-related proteins (E-cadherin, fibronectin, g-catenin, vimentin, N-cadherin) in control and Kindlin-1 cells. C) Immunostaining of E-cadherin, ZO-1, N-cadherin, and vimentin in the MCF7 transfectants. Cells were seeded on laminin substrate (5 µg/mL). Cells were then stained with PBS containing 1 µg/mL DAPI (diamidino-2-phenylindole) to visualize the nuclei. Epithelial and mesenchymal markers were labeled with the same antibodies as used for western blots, except for mouse monoclonal anti-ZO-1 antibody (1/ZO-1 clone, 1:5000, BD Biosciences). Scale bar = 20 µm. D) Fluorescence staining of F-actin and E-cadherin in the MCF7 transfectants at higher magnification. F-actin was localized using fluorescent-labeled phalloidin conjugated to tetramethylrhodamine isothiocyanate (Sigma-Aldrich) at a dilution of 1:100 of a methanolic stock (200 U/mL) solution. The arrow indicates a partial cytoplasmic relocalization of E-cadherin. Scale bar = 20 µm. E) MCF7 cells were transfected with the wild-type or mutant pGL3-E-cad reporter construct in the presence or absence of Kindlin-1. The luciferase activity was determined and normalized to an internal control. Data are representative of two independent experiments performed in triplicate. Means and upper 95% confidence intervals are shown for triplicates of one experiment. Difference in fold change for wild type CDH1 promoter activity: P = .001, for mutant CDH1 promoter activity: P = .2, two-sided Student t test. F) Expression of EMT-related transcriptional factors zinc finger protein SNAI1, zinc finger protein SNAI2, and twistrelated protein TWIST1 in stable MCF7 transfectants was analyzed by immunoblotting. CDH1 = E-cadherin; EMT = epithelial-mesenchymal transition; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; SNAI1 = snail homolog 1; SNAI2 = snail homolog 2; TWIST1 = twist homolog 1. Finally, we used the specific TGFbR1 kinase inhibitor SB431542 to ascertain whether Kindlin-1-induced EMT would require signaling through the TGFb receptor. This inhibitor prevented the phosphorylation of Smad2 (Figure 5, D) and the TGFb-induced EMT in Kindlin-1 cells (Figure 5, E) . Together, these data suggest that Kindlin-1-induced EMT is TGFb dependent.
Notably, after exposure to TGFb, Kindlin-1-siRNA-treated HMECs maintained cell-cell adhesion and partially retained their original cobblestone-like epithelial morphology ( Figure 6, A, B) . In contrast, control cells treated with TGFb lost their cell-cell contacts and displayed a fibroblast-like morphotype (Figure 6, B) . Consistently, the depletion of the E-cadherin and b-catenin epithelial markers induced by TGFb was suppressed in Kindlin-1-silenced cells. Similarly, the induction by TGFb of the mesenchymal markers vimentin, fibronectin, and a-actin was repressed in Kindlin-1-silenced cells (Figure 6, C) . These results indicate that kindlin-1 suppression restricted the TGFb-dependent EMT phenotype.
Effect of Kindlin-1 Knockdown on Primary Breast Tumor Growth and Lung Metastasis
To further investigate whether Kindlin-1 may regulate invasive tumor growth and lung metastasis, we used the highly metastatic 4T1 syngeneic mouse model in which kindlin-1 expression was depleted. The orthotopic injection of Kindlin-1 shRNA-4T1, or control shRNA-4T1 cells (n = 6 and 10, respectively) into the mammary fat pad of syngeneic BALB/c mice led to the formation of primary mammary tumors in all mice. However, the mean tumor size in Kindlin-1-knockdown mice was statistically significantly lower (85% decrease) than in control mice (mean tumor size, Kindlin-1-depleted cells vs control cells, 0.36 cm 3 vs 2.46 cm 3 , difference = 2.10 cm 3 , 95% CI = 1.21 to 2.98, P < .001, Figure 7, A and B) . Notably, immunohistochemistry of tumors derived from our mouse model showed that the Kindlin-1-silenced tumors exhibited higher E-cadherin levels with more membranous staining than control tumors (Figure 7, C) . Taken together, these data suggest that properties of the EMT are manifest in Kindlin-1-expressing cells in vivo and are weakened when Kindlin-1 is silenced.
Finally, we assessed the effect of kindlin-1 depletion on the lung metastatic potential of breast cancer cells ( 
Discussion
To our knowledge, this is the first study to show that kindlin-1 expression in breast tumors is associated with lung metastasis and lung metastasis-free survival. We provide evidence that kindlin-1 is potentially a clinically relevant mediator of lung metastasis in breast cancer and possibly other carcinomas metastasizing to the lung such as colon cancer, for which overexpression of kindlin-1 was previously reported in a small cohort of patients (seven of 10 patients) (55) . In addition, we show that kindlin-1 is overexpressed in lung primary tumors, in which 60-fold increased expression of the gene was previously described (six of 10 lung tumors) (55) . Importantly, Kindlin-1 expression is strongly associated with metastasis-free survival of patients with lung adenocarcinomas.
In addition, our in vitro studies showed that kindlin-1-expressing cells displayed increased proliferation, clonogenicity, and invasion, which are hallmarks of the initiation and progression of primary cancers to metastasis (3, 7) . Our data are consistent with previous reports on Kindler syndrome keratinocytes and Kindlin-1-deficient mice showing decreased proliferation, impaired cell adhesion, and delayed cell spreading (26, 56, 57) . Although a higher propensity to develop cancer has been suggested for Kindler syndrome patients, there is a clear distinction between this inherited disease in which Kindlin-1 is inactivated and the sporadic cancers reported here in which Kindlin-1 is wild type and overexpressed. The mechanisms underlying skin cancers in Kindler Syndrome are likely to be different from the Kindlin-1 alterations described here.
Consistent with the role of kindlin-1 in the progression of human cancers, we have shown that Kindlin-1 silencing prevented tumor growth and lung metastasis in mice using an orthotopic and syngeneic breast tumor model. Although metastasis-associated genes are usually not involved in the growth of primary tumors, kindlin-1, like some other mediators of breast cancer metastasis to the lungs (12, 30) , may facilitate both breast tumorigenicity and lung metastasis. However, we did not find any association between kindlin-1 expression and breast tumor size in clinical human breast cancer patients. Indeed, a multivariable analysis assessing Kindlin-1 expression and tumor size in our validation breast tumor dataset (n = 721) showed that Kindlin-1 was an independent predictor of lung metastasis (not shown).
Kindlin-1 has been shown to be an essential regulator of integrin signaling and cellular adhesion to the ECM proteins such as fibronectin and laminin (22) . A recent study (58) demonstrated that b1 integrin signaling is a critical regulator of the proliferation of micrometastatic breast cancer cells in lungs. Furthermore, this process was dependent on the activation of focal adhesion kinase (FAK), which is, like b-integrins, a binding partner of kindlin-1 (59) . Thus, the possible implication of the integrin-FAK axis in kindlin-1-mediated lung metastasis is not excluded. Because integrins and adhesion to ECM components may regulate cadherindependent cell adhesion mechanisms, kindlin-1 might function at the intersection of multiple signaling pathways and cellular functions during neoplasia.
We have provided evidence that kindlin-1 initiates TGFbdependent EMT operating through reduced expression and relocalization of E-cadherin coupled with the induction of several mesenchymal markers such as N-cadherin and fibronectin. Both TGFb and EMT are potent components of signaling and cellular alterations involved in cancer initiation, invasive growth, and metastasis (60) . Most notably, transduced cancer cells expressing kindlin-1 exhibit a constitutive TGFb-dependent activation of the canonical TGFb signaling elements Smad-2 and Smad-3 coupled with the transcription of several TGFb and Smad-inducible genes such as CTGF, EDN1, and MMP9, which are known to be involved in breast cancer progression. In line with our findings, TGFb has been shown to enhance lung metastasis formation in several transgenic mouse models (61, 62) . More recently, a TGFb response gene signature was shown to predict lung metastasis in human breast cancer (53) . The authors demonstrated that TGFb signaling in the breast tumor microenvironment primes cancer cells for metastasis to the lungs (53) .
This study has several potential limitations. First, we were not able to assess the prognostic value of Kindlin-1 expression in other cancers metastasizing to the lung because of the lack of documented clinical follow-up. In future investigations, it will be important to determine the involvement of Kindlin-1 in large and well-documented cohorts of colon and bladder cancer patients. Second, our study did not explain in detail the reciprocal crosstalk between kindlin-1 and TGFb in EMT. Clearly, kindlin-1 may provide a new link between TGFb, the ECM, and cell-cell adhesion systems in the tumor microenvironment. Although, our results suggest interdependent functions of kindlin-1 and TGFb in the fine-tuning of EMT and neoplasia, the molecular dissection of this reciprocal crosstalk needs further investigations.
In conclusion, our study suggests that the role of kindlin-1 in human cancers should be assessed further and its possible value for guiding diagnostics and therapeutics considered. First, Kindlin-1 analysis can be used to identify breast cancer patients with higher risk of developing lung metastasis. Second, targeting kindlin-1 function may be an effective strategy for blocking the EMT and metastasis. Given the importance of the EMT and lung metastasis in the progression of other tumor types, Kindlin-1 may also have much broader clinical utility relevant to other cancer types.
